In late 2012, the FDA approved tofacitinib (Xeljanz®, from Pfizer), which was initially designed as a specific inhibitor of JAK1 and JAK3 kinases; tofacitinib has also been administered as an immunosuppressant for the treatment of transplant patients and individuals with autoimmune diseases (36). The gene discussed is JAK1; the disease is autoimmune disease.